Compositions and methods for the treatment and diagnosis of cancers associated with surface k-ras
AssigneesUniversity of Maryland, Baltimore, University of Maryland, College Park
InventorsAlexander Sasha KRUPNICK, Anirban BANERJEE, Amy J. KARLSSON, Eric Reed LAZEAR, Shaun Maxwell STEWART
Life of this patent
Estimating the term…
Abstract
The present disclosure describes compositions and methods for treating and diagnosing cancers that express K-Ras on the external surface of cancer cells, and novel antibody-drug conjugates for use in such methods.
Claims19
-47. (canceled)
A composition comprising:
- a means for binding with specificity to a Surface K-Ras Antigen expressed on an external surface of a cancer cell;
- and
- a therapeutic agent, wherein the means is linked to the therapeutic agent to form a therapeutic complex, wherein neither the composition nor the therapeutic complex comprises an intracellular delivery compound.
A chimeric antigen receptor comprising an extracellular domain, a transmembrane domain, and an endodomain, wherein the extracellular domain comprises a means for binding with specificity to a Surface K-Ras Antigen expressed on an external surface of a cancer cell.
A chimeric antigen receptor comprising an extracellular domain, a transmembrane domain, and an endodomain, wherein the extracellular domain comprises an antibody fragment, wherein the antibody fragment comprises a heavy chain variable domain comprising a heavy chain CDR set of the sequences of SEQ ID NO:
- 10, 11, and 12, and a light chain variable domain comprising a light chain CDR set of the sequences of SEQ ID NO:
- 14, 15, and 16.
A bispecific binding complex comprising:
- a first means for selectively binding to a Surface K-Ras Antigen expressed on an external surface of a cancer cell;
- and
- a second means for selectively binding to an antigen expressed on a surface of an immune effector cell, wherein the first means is linked to the second means.
The method of 64, wherein the cancer cells are selected from the group consisting of pancreatic cancer cells, lung cancer cells, cholangial cancer cells, ovarian cancer cells, endometrial cancer cells, or colorectal cancer cells.
Dependencies are inferred from the claim text.